key: cord-0053706-8ejvsa2i
authors: Zheng, Wenjin; Xu, Qing; Zhang, Yiyuan; Xiaofei, E.; Gao, Wei; Zhang, Mogen; Zhai, Weijie; Rajkumar, Ronaldjit Singh; Liu, Zhijun
title: Toll-like receptor-mediated innate immunity against herpesviridae infection: a current perspective on viral infection signaling pathways
date: 2020-12-09
journal: Virol J
DOI: 10.1186/s12985-020-01463-2
sha: 0c6b077b6b6c1d7eeaad0a5af1f2a43a3b55e12c
doc_id: 53706
cord_uid: 8ejvsa2i

BACKGROUND: In the past decades, researchers have demonstrated the critical role of Toll-like receptors (TLRs) in the innate immune system. They recognize viral components and trigger immune signal cascades to subsequently promote the activation of the immune system. MAIN BODY: Herpesviridae family members trigger TLRs to elicit cytokines in the process of infection to activate antiviral innate immune responses in host cells. This review aims to clarify the role of TLRs in the innate immunity defense against herpesviridae, and systematically describes the processes of TLR actions and herpesviridae recognition as well as the signal transduction pathways involved. CONCLUSIONS: Future studies of the interactions between TLRs and herpesviridae infections, especially the subsequent signaling pathways, will not only contribute to the planning of effective antiviral therapies but also provide new molecular targets for the development of antiviral drugs.

The herpesviridae family comprises a large group of enveloped DNA viruses characterized by latent infection in their hosts. Currently, eight family members are known to be associated with widespread human infection ( Table 2 ). Upon detecting members of this family, TLRs recruit adaptor proteins, including myeloid differentiation factor 88 (MyD88), TIR-domain-containing adaptorinducing interferon-β (TRIF), TIR-domain-containing adaptor protein (TIRAP), and TRIF-related adapter molecule (TRAM). This is followed by signal transmission to activate transcription factors including nuclear factor kappa B (NF-κB), activator protein-1 (AP-1), and interferon regulatory factors (IRF3/7). These factors enter the nucleus, stimulating transcription to promote proinflammatory cytokines and interferon (IFN) expression [5, 6, 28] . The inflammatory cascades defend against viruses while also injuring the host. Under physiological conditions, regulatory systems function in the host to inhibit excessive activation of the TLR signaling pathways to maintain homeostasis; these include Annexin A2, the ubiquitin ligase TRIAD3A, RP105, and acetylation of lysine residues [29] [30] [31] [32] . Here, we clarify the mechanism underlying the human TLR-mediated innate immune response against herpesviridae in the activation and reactivation of virus infection.

Herpes Simplex Virus (HSV) infection is a worldwide cause of severe medical conditions such as encephalitis, keratitis, and neonatal herpes [94, 95] . It has two serotypes, HSV-1 and HSV-2, which primarily infect individuals through epithelial cells. After initial infection, it forms a latent infection in ganglia and latency-associated transcripts are expressed [96] . HSV US3 protein inhibits TLR3 responses in cultured human monocytes [97] . Similarly, HSV immediate-early ICP0 protein suppresses the TLR2-mediated innate immune response and NF-κB signaling [98] . HSV downregulates TLR2 and TLR4 in a THP-1 monocyte cell line [99] . These findings reveal the evasion mechanism of HSV. When host immunity is weak, HSVs begin to reactive to establish infection.

Studies have revealed that TLR2, TLR3, TLR4, and TLR9 are capable of recognizing specific components of HSV such as glycoprotein B (gB), glycoprotein H (gH), glycoprotein K (gK), glycoprotein L (gL), and US2 protein in the activation and reactivation of HSV [100] [101] [102] [103] [104] [105] . TLR signaling activates the transcription of immune response genes by inducing the secretion of intracellular protein signaling molecules such as interleukins (ILs) and interferons (IFNs) to protect the host. Furthermore, TLR2 and TLR9 have been shown to synergistically fuel innate immunity to defend against HSV-1 and -2, showing a protective effect [102, 106] .

Upon invasion of HSV-1 and -2, viral glycoproteins including gH and gL are recognized by TLR2 [107] . TLR2 is located on the dendritic cell surface and hetero-dimerizes with TLR6 or TLR1 to recognize viral glycoproteins [108] . Once HSV-2 has invaded the host, TLR4 recognizes the short-hairpin DNA from HSV on the cell surface [109] . Villalba et al. reported that TLR2 and TLR4 expression occurs as early as 1 h after HSV-1 infection and increase the levels of IRF3, IRF7, INF-β, and IL-6 [110] . The activation of TLR2 or TLR4 launches the MyD88-dependent signaling cascades and assembles macrophages and natural killer cells [109, 111] . MyD88 recruits IL-1 receptor-associated kinase 1 (IRAK1), then activates tumor necrosis factor receptor-associated factor (TRAF6) [112] [113] [114] [115] . Subsequently, transforming growth factor-β-activated protein kinase-1-binding protein-2 (TAB2) and transforming growth factor-β-activated kinase-1 (TAK1) are recruited to stimulate the inhibitor of nuclear factor κB kinase (IKK) complex which comprises IκB kinase α (IKKα), IKKβ, and IKKγ (NEMO) [113, 116, 117] . IKKα serves as a stimulator of NF-κB in the IKK complex. In contrast, IKKβ phosphorylates and degrades the inhibitor of NF-κB (IκB) to release NF-κB [118, 119] . Alternatively, mitogen-activated protein kinases (MAPKs) are triggered by TAK1 to allow AP-1 into the nucleus [120] [121] [122] [123] [124] . NF-κB and AP-1 enable immune cells to secrete IL-15, TNF-α, and IFN to defend against HSV and counteract viral absorption. In addition, studies have demonstrated that the expression of chemokines, such as chemokine (C-C motif ) ligands 7, 8, and 9, as well as chemokine (C-X-C motif ) ligands 1, 2, 4, and 5, which play important roles in the innate immune response against HSV [125, 126] . Surprisingly, when activated via the TLR4-MyD88 axis, AP-1 upregulates TLR4 expression by feedback in genital epithelial cells to enhance immunity in humans [127] . A study has also shown that Sp1 has a significant effect as a major transcription factor involved in TLR2 promoter activity [107, 128] . Moreover, Kurt-Jones et al. demonstrated that neonates produce more pro-inflammatory cytokines than adults, which may explain the sepsis syndrome that is seen with HSV-1 and -2 [129] . This result is in accord with the finding that TLR2-deficient mice are more likely to survive HSV-1 than wild-type mice [105] . Besides the cytokine response, TLR2 signaling generates reactive oxygen species and induces oxidative stress, which cause damage in wild-type microglial cell cultures; but this does not occur in cells from TLR2deficient mice. The consequences of oxidative stress are associated with reduced activation of the MAPK pathway [130] . These results suggest that the immune response mediated by TLR-2 can be not only beneficial but also detrimental to the host [105] . Surprisingly, TLR2 and TLR9 synergistically activate the innate antiviral response defense against HSV-1 and -2, showing a protective effect [106] . Compared to TLR2, TLR3 seems to have a protective effect [131, 132] .

Upon identification of invasive HSV-1 and -2, the host cells form endosomes that spontaneously wrap up the virus. Unc-93 homolog B1 (UNC-93B) is a transmembrane protein localized on the endoplasmic reticulum (ER) that transfers TLR3, 7, 8, and 9 from the ER to the endosome [133] [134] [135] [136] . Upon HSV-1 and -2 stimulation, TLR3 interacts with UNC-93B1 and shifts from the ER to endosome [134, 135] . In the endosome, TLR3 is phosphorylated by tyrosine kinase c-Src, epidermal growth factor receptor (EGFR), and phosphatidylinositol 3-kinase (PI3K) to form dimeric TLR3, which initiates a downstream signaling pathway. Although a mutual action between HSV RNA and TLR3 has not yet been demonstrated, it is likely that HSV-1 and -2 produce dsRNA that serves as a ligand for TLR3 [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] . The activation of TLR3 recruits TRIF and TRAF [148, 149] . TLR3 is the only member of the TLR family that can recruit TRIF and TRAF as the signal transduction factor, instead of MyD88. Upon TRIF recruitment, TANKbinding kinase-1 (TBK1), inhibitor of nuclear factor κB kinase ε (IKKε), NAK-associated protein 1 (NAP1), and TRAF3 constitute a signaling complex that leads to the activation of IRF3/IRF7 and NF-κB [150] [151] [152] [153] [154] [155] [156] [157] . The activation of IRF3 and NF-κB induces the production of IFNβ, TNF-α, and IL-6 [158, 159] . Meanwhile, TRAF recruits the downstream protein receptor interacting protein 1 (RIP1), which subsequently recruits TAB2 and TAK1 to form a complex to trigger IKKα and IKKβ [160] [161] [162] . These two kinases with the IKK receptor protein IKKγ (NEMO) constitute the IKK complex [163] . IKKα activates downstream NF-κB, while IKKβ phosphorylates the inhibitor of NF-κB (IκB) leading to the degradation of IκB [119, 161] . The complex formed by TAB2 and TAK1 also activates AP-1 via MAPKs [164] . Subsequently, NF-κB, AP-1, and IRF3/IRF7 enter the nucleus and facilitate the release of IFN-β, TNF-α, and IL-6 to defend against HSV [165, 166] (Fig. 1 ).

TLR9 is one of the crucial components in the defense against HSV-1 and -2. Similar to TLR3, TLR9 is stabilized by UNC-93B1 through preventing its degradation and transporting it from the ER to the endosome [136] . This redistribution of TLR9 is associated with cytosine-phosphate-guanine DNA (CpG DNA). Both HSV DNA and CpG oligonucleotides contain abundant CpG motifs [167, 168] . CpG DNA drives TLR9 to shift into early endosomes and CpG oligonucleotides access the endosome. Subsequently, the oligonucleotides assemble and form a secondary structure near the core CpG motif to activate TLR9 [3, 169, 170] . Guanosine triphosphatases (Rab GTPases) mediate the maturation of endosomes. Upon maturation, endosomes that contain CpG DNA combine with lysosomes. The hallmark of the maturation of endosomes involves the formation of endolysosomes [171] [172] [173] . On the endosomal membrane, Rab5 mediates class III phosphatidylinositol-3 kinase to produce phosphatidylinositol-3 phosphate that interacts with Rab5 to regulate and promote the maturation of early endosomes [174] [175] [176] . Furthermore, MyD88 activates IRAK1/4 to trigger the protein TRAF6. Subsequently, TRAF6 recruits and activates TAK1 (transforming growth factor-β-activated kinase 1) through the K-63linked poly-ubiquitination of TAK1 and TRAF6 [177] [178] [179] . TAK1 initiates downstream cascades, including MAPKs and the NF-κB-inducing kinase (NIK)-IKK-IκB signaling pathway [180, 181] . In this pathway, NF-κB is isolated and inactivated in the cytoplasm primarily by IκB. The proteolysis of IκB is regulated by the activation of IKKs including IKKα, IKKβ, and IKKγ [182, 183] . Activated IKKβ leads to the phosphorylation and proteolysis of IκB [182] . NF-κB is unlocked and subsequently enters the nucleus. These processes induce the activation of transcription factors such as AP-l and NF-κB, directly facilitating the downstream gene expression of IL-10, IL-12, TNF-α, and IFN-β [180, [184] [185] [186] (Fig. 1 ).

TLR-mediated signaling pathways in response to HSV. Upon HSV ligand stimulation, TLR2, TLR4, and TLR9 recruit the adaptor MyD88. Once recruited, MyD88 binds the protein complex composed of IRAK and TRAF6. TRAF6 results in the phosphorylation of TAK1, which then activates the IKK complex that results in the phosphorylation and degradation of IκB. The degradation of IκB allows NF-κB to translocate into the nucleus. Alternatively, TAK1 activates the MAPK pathway, triggering the activation of AP-1. Under HSV stimulation, TLR3 is localized and phosphorylated by tyrosine kinase c-Src, EGFR, and PI3K in the endosome. Moreover, TLR3 triggers TRIF to enable TBK1, IKKε, NAP1, and TRAF3 to generate a complex. Furthermore, this complex leads to the activation of IRF3/IRF7 and NF-κB. TLR3 recruits TRAF and RIP1 to phosphorylate TAB2 and TAK1. The complex formed by TAB2 and TAK1 activates AP-1 via the MAPK pathway and NF-κB via the IKK complex-IκB pathway. Together, NF-κB, IRF3/IRF7 and AP-1 induce the expression of inflammatory cytokines to protect the host by innate immunity

Varicella zoster virus (VZV) causes chicken-pox in the primary infection. In elderly or immunosuppressed patients, reactive VZV can cause herpes zoster after latency [187] . During the latency, VZV downregulates the surface expression of the NKG2D ligands of ULBP2 and ULBP3, which reduce the activation of natural killer cells in the presence of VZV [188] .

Studies have reported that TLR2, TLR3, and TLR9 play crucial roles in the activation and reactivation of VZV [189] [190] [191] . TLR9 induces plasmacytoid dendritic cells (pDCs) to secrete IFN-α via the MyD88 signaling pathway involved in infection by VZV [191] . In addition, VZV triggers monocytes and macrophages to produce NF-κB via TLR2 and allows the secretion of the antiviral factor IL-6, but TLR2, TLR3, and TLR4 are not involved in the IFN-α production induced by VZV infection [189, 192] . Besides, studies have demonstrated that TLR3 is involved in the recognition of VZV [193] . There is no evidence that the expression of TLRs on non-immune cells react to infection with VZV. However, unlike other herpesviruses, the cytokine response to VZV is species-specific. VZV does not induce cytokines in mouse embryonic fibroblasts or in a mouse cell line, but it does trigger NF-κB in a human cell line expressing a mouse TLR2 construct [189] .

Epstein-Barr virus (EBV/HHV-4) is primarily transmitted via saliva. It proliferates in oropharyngeal epithelial cells, infects B lymphocytes, and enters the bloodstream to cause systemic infection. During the latency, the EBV lytic protein BGLF5 targets TLR9 mRNA for degradation in EBV-infected B cells, reducing the function of TLR9 [194] . Moreover, BGLF5 also targets TLR2 in infected cells [195] . In addition, a late lytic tegument protein, BPLF1, prevents TLR-mediated IFN production [196] . Besides, EBV-encoded miRNAs inhibit the TLR signaling pathway [197] .

In the activation and reactivation of EBV, a membrane receptor expressed on the surface of B lymphocytes, TLR2 unites with TLR1 or TLR6 to form a hetero-dimer, which combines with lipoproteins or lipopeptides to serve as an active signaling complex. The TLR heterodimer (TLR2/TLRx) is the key to recognizing EBV. Eric Gaudreault et al. found that infectious and UV-inactivated EBV induce NF-κB activation and the secretion of primary monocyte chemotactic protein in a TLR2-dependent manner [198] . TLR2 activation initiates the MyD88-dependent signaling cascades. MyD88 recruits IRAKs, including IRAK1 and IRAK4, which stimulate TRAF6 and phosphorylate IKK, IκB, and NF-κB [199] .

When EBV penetrates a cell, it transcribes small noncoding RNAs called EBERs by using the host RNA polymerase III, and TLR3 is activated in the ER. EBERs induce inflammatory responses through TLR3 and neural precursor cells, resulting in high levels of cytokines such as TNF-α and IL-6. In addition to acting as an inflammatory mediator, NF-κB is capable of upregulating the expression of EBERs and LMP1 (EBV latent membrane protein 1), thereby triggering moderate inflammation [200, 201] . EBERs promote LMP1 transcription through NF-κB. Conversely, MP1 also stimulates NF-κB to increase the expression of EBERs. This positive regulatory loop becomes a necessary driving force for the inflammatory-carcinogenic transformation of EBVinfected epithelial cells.

Furthermore, the EBV genome encodes two membrane proteins, LMP1 and LMP2, that act as natural signals of B-cell activation. LMP1 and LMP2 are required for the interaction of the ligand with the CD40 receptor and B-cell receptor. Martin et al. found that the TLR signaling pathway is a third pathway for activated B lymphocytes [202] . They reported that, after EBV infection of B lymphocytes, EBV gene expression transcribes ssRNA that stimulates TLR7 signaling, resulting in up-regulation of the TLR7 and MyD88 genes to activate IRF-5 and IRF-7 [203] . IRF-5 and NF-κB synergistically trigger cytokine promoters to induce the production of inflammatory cytokines. Moreover, they also provide a signal equivalent to the CD40 ligand to promote B cell activation and expansion in the initial phase of EBV infection. Therefore, it has been suggested that, in the early stage of infection, EBV stimulates TLR7 signaling to promote the initial stage of B cell activation and expansion. Subsequently, EBV induces negative-regulatory factors of the TLR7 pathway, which are necessary for the establishment of latency.

In the primary infection, EBV initiates progressive lytic infection by expressing BZLF-1, which is the immediateearly lytic EBV gene and regulates the productive replication of EBV [204] . CpG oligodeoxynucleotide 2006 triggers innate immunity via the TLR9 of B cells to substantially inhibit BZLF-1 mRNA expression in acute EBV infection ex vivo and in Akata Burkitt lymphoma cells with latent EBV infection stimulated by anti-IgG. This reaction is mediated by IL-12 and IFN-γ [205] . When triggering TLR9, B cells infected with EBV ex vivo efficiently transform by reducing the initiation of lytic EBV infection, and thereby reinforcing the maintenance of EBV latency [206] .

The newly-formed EBV DNA in virus-infected cells contains an unmethylated CpG dinucleotide sequence. When the newly-formed virion is subsequently released, this dinucleotide is considered to be the main trigger of TLR9 [207] . After TLR9 recognizes EBV DNA, IRAK-1 and TRAF6 are activated by phosphorylation, thereby eliciting the IKK complex, resulting in NF-κB expression [180] . Subsequently, NF-κB promotes the production of inflammatory cytokines such as TGF-β, IL-6, IL-1, IL-23, and IL-21 [207] . These cytokines induce Th17 cells to secrete IL-17A, causing the recruitment of neutrophils and macrophages to infected sites and triggering the secretion of various pro-inflammatory mediators by various cell types. Salloum et al. treated mouse peripheral blood mononuclear cells with EBV DNA in the presence or absence of the TLR9 inhibitor oligodeoxynucleotide 2088, and showed that TLR9 inhibitors significantly decrease IL-17A production and play a crucial role in promoting IL-17A secretion [208] (Fig. 2) .

Human cytomegalovirus (HCMV) is an important cause of disease in the immunodeficient host and the most common intrauterine infection in humans [209] . Acquired during early life, HCMV persists in a latent state for the life of the individual. Inflammatory cytokines can cause an innate immune response in the host. Through different effector cells (such as antigenpresenting cells [APCs], natural killer [NK] cells and Fig. 2 Mechanism of responses of TLRs to EBV and HCMV. EBV activates the MyD88 pathway or the MyD88-independent pathway via the viral envelope and products. Upon EBV stimulation, TLR2, TLR3, TLR7, and TLR9 inside and outside the cells induce NF-κB or IRF-5/7 by a series of protein kinases to produce cyto-inflammatory factors. MyD88 recruits TRAF6 and IRAKs to activate the IKK complex composed of IKKα, IKKβ, and NEMO. Besides acting as an inflammatory mediator, NF-κB also upregulates the expression of LMP1 to trigger moderate inflammation. Similarly, HCMV reacts with TLRs, including TLR2, TLR3, TLR4, and TLR9, through the viral envelope or products. MyD88-NF-κB is the main pathway. However, dsRNA from CMV also activates IRF-3 and TLR3 to promote the expression of inflammatory factors. Meanwhile, the CMV-encoded miR-UL112-3p inhibits activation of the TLR2/NF-κB pathway, as well as the expression of various cytokines phagocytes), anti-inflammatory cytokines, and IFNs respond to act against HCMV infection. The early release of IFN-I and other pro-inflammatory cytokines limits the spread of infection by establishing an "antiviral state" that triggers an efficient adaptive immune response to achieve latency and persistence [210] . To achieve latency, the HCMV-encoded US7 and US8 proteins impair the activation of TLR3 and TLR4 [211] . Similarly, the HCMVencoded US9 protein reduces stimulator of interferon genes (STING) signaling and the production of IFN [212] . In addition, the HCMV tegument protein UL82 inhibits STING-mediated signaling to evade the antiviral immune response [213] .

Generally, researchers have shown that TLRs 2-5 and TLR9 play crucial roles in the immune response to the activation of HCMV [50, 67, [214] [215] [216] [217] . TLR2 recognizes the viral envelope glycoproteins gB and gH. Together with TLR1 or TLR6, TLR2 activates the MyD88-dependent and downstream transcription factor NF-κB signaling pathway to induce a series of pro-inflammatory cytokines, chemokines, and adhesion molecules, such as IL-6 and IL-8 [218] [219] [220] . MyD88 recruits TRAF6 and IRAKs to activate IKKα and IKKβ, together with NEMO, to form the IKK complex. IKKα triggers downstream NF-κB, while IKKβ phosphorylates the NF-κB inhibitor IκB, leading to its degradation [160, 161, 163] . This process results in the production of inflammatory cytokines. For example, IFN-γ stimulates a variety of innate immune cells and immune effector cells to develop the adaptive immune response and exert an antiviral effect [221] . MicroRNAs are small non-coding RNAs that cooperate with viral proteins to regulate the expression of viral and/or host genes, and they are involved in the immune evasion of infected cells, as well as the latency and reactivation of HCMV [222] . CMV-encoded microRNAs have also been shown to downregulate TLR2 expression [217] . Using an in-silico method, this study postulated that HCMV microRNAs trigger the TLR innate immune pathway; specifically, TLR2 might be a target for HCMV miR-UL112-3p. Because miR-UL112-3p is expressed after virus entry, downregulation of TLR2 occurs in the late stage of lytic infection. Immunoblot analysis of miR-UL112-3p-transfected cells revealed that it induces the reduction of endogenous TLR2 expression. The microRNA-mediated downregulation of TLR2 affects innate signal transduction, significantly inhibiting the activation of the IRAK1 and NF-κB pathways located in the TLR2/NF-κB signaling axis of the upstream kinase, as well as the expression of various cytokines such as IL-1β, -6, and -8. TLR2 protein levels decrease in the late stage of HCMV infection, and this is associated with the accumulation of miR-UL112-3p in fibroblasts and mononuclear THP1 cells.

TLR3 and TLR5 are also critical factors in the CMV infection pathway. TLR3 targets TRIF as a downstream adapter molecule instead of the adaptor protein MyD88 [149] . TLR3 activates the signaling complex assembled by TRIF. As a factor downstream to TRIF, TBK1 forms NAP1 and TRAF3 to elicit phosphorylation of the transcription factor IRF3, which produces inflammatory factors such as IFN-β [154-156, 221, 223] . CMV stimulates mast cells through the TLR3/TRIF signaling pathway to transmit effector functions. Subsequently, these cells release a large number of pro-inflammatory and antimicrobial mediators, many of which are stored in granules and released after degranulation, to enhance their protective properties and attract supplemental CD8 T cells to extravascular sites of viral replication [216] . During HCMV infection/reactivation, TLR5 plays an atypical role, probably because of the indirect effects of immunomodulation and immunostimulation on HCMV responses.

HCMV also promotes macrophage-mediated inflammatory responses through TLRs. HCMV infection stimulates cluster differentiation antigen 14 (CD14), TLR2, TLR4, and TLR5 on the surface to enhance the intracellular expression of the adaptor protein MyD88, and phosphorylation of IκB and NF-κB, thereby increasing the response of macrophages to viral components. The protein and mRNA levels of MyD88 are significantly elevated in macrophages. MyD88 combines with the cytoplasmic Toll/IL-1 region and triggers the phosphorylation of IRAK4, followed by the recruitment and phosphorylation of IRAK1, which then leads to the release of TNF-6 and transmission of the NF-κB signaling cascade [115, [224] [225] [226] [227] [228] . These mechanisms promote ligand-induced pro-inflammatory cytokine mRNA expression and the production of TNF-α, IL-6, and IL-8 proteins.

TLR9, a pattern recognition receptor for HCMV in natural IFN-producing cells and DCs, recognizes unmethylated CpG motifs in viral DNA to initiate the transduction of intracellular signals by the adapter molecule MyD88, ultimately leading to the activation and transcription of NF-κB. Therefore, phosphorylated NF-κB encodes pro-inflammatory cytokines and chemokines, such as IFN-α and IL-12, to promote NK cells that recognize MCMV-infected cells by activating the receptor Ly49H [229, 230] . Ly49H interacts with the MCMV-encoded protein m157 on the surface of infected cells, resulting in elimination of the virus by NK cells [67] (Fig. 2) .

HHV-6 causes the exanthema subtype; it preferentially infects functional immune cells and elicits various immunobiological changes [231] [232] [233] [234] . Murakami et al. pointed out that HHV-6 infection significantly effects TLR4induced cytokine levels [235] . This report revealed that TLR4 and the adaptor molecule MyD88 are significantly increased in HHV-6-infected cells. On the contrary, the phosphorylation levels of TAK-1, IKKα/β, and IκBα are reduced and affect the expression of NF-κB [236] . Therefore, upon stimulation of the TLR4 ligand, the ability of HHV-6-infected DCs to produce IL-10 and IL-8 is significantly impaired. This indicates that, in HHV-6-infected DCs, the disruption of TLR4 signaling is caused by a block in the downstream signaling pathway.

HHV-6 and -7 participate in the pathogenesis of pityriasis rosea through TLRs. In HHV-7-positive cases, the expression levels of TLR2 and TLR4 are notably increased, while TLR9 and the HHV-7 viral load are positively correlated [237] . Interestingly, there is an interaction between HHV-6 and HHV-7: HHV-6 can be reactivated by HHV-7 infection [238] .

Kaposi's sarcoma-associated herpesvirus (KSHV), also named human herpesvirus-8, is well correlated with several forms of cancer such as Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease [239] . Like other herpesviruses, KSHV also causes latency in the host. During the latency, KSHV viral interferon regulatory factors (vIRFs) inhibit TLR3-mediated IFN induction [240] . Moreover, the replication and transcription activator (RTA) protein from KSHV triggers proteasomal degradation of the TLR3 adaptor protein TRIF, which blocks the subsequent pathway [241] . RTA also prevents TLR4 signaling via the degradation of MyD88 [242] . West et al. first reported that KSHV upregulates the TLR3 pathway during infection to induce TLR3specific cytokines and chemokines such as IFN-1β and CXCL10 (IP-10) [243] . Furthermore, researchers have determined that TLR9 is the major receptor for KSHV. Once pDCs are infected, KSHV upregulates TLR9, CD83, and CD86, causing pDCs to produce IFN-α [244] .

In addition, TLR4 plays an essential role in innate immunity to KSHV. KSHV microRNA clusters (particularly miRNA-K1, -K3, and -K11) trigger TLR4 with its coreceptors, CD14 and myeloid differentiation protein 2, to activate the MyD88-NF-κB pathway and produce IL-1β, IL-6, and IL-18 [245] . In addition, Lagos et al. found that KSHV suppression of TLR4 expression is the mechanism of immune escape during KSHV infection in endothelial cells [246] . Moreover, KSHV inhibits the TLR2 signaling pathway after infection in macrophages. In addition, the replication of KSHV and the transcriptional activator RTA/ORF50 block the TLR2 and TLR4 signaling pathways via reducing the expression of functional proteins. Moreover, KSHV-encoded microRNAs reduce the inflammatory factor expression by modulating two components of the TLR/IL-1R pathway, IRAK1 and MyD88 [247] . Thus, KSHV uses two mechanisms to avoid attack by the host immune system, leading to repeated infection in the host [248] .

To date, studies have shed light on the interactions between TLRs and herpesviridae infections, especially the subsequent signaling pathways. Research continues to reveal new insights into TLR pathways and their roles in host defense responses, especially in innate immunity [249] [250] [251] . However, the detailed mechanisms of mutual action between HSV RNA and TLR3 remain unclear [138] [139] [140] 148] . Moreover, understanding the mechanisms of activation and regulation in detail will help in the design of efficient vaccines and therapeutics based on modulating the TLRs more precisely. In this context, the use of TLR antagonists and regulators such as MPL, topical SMIP-7.7, Annexin A2, ubiquitin ligase TRIAD3A, pathogenesis-related protein from Oenanthe javanica, and RP105 might have broader applications [29, 31, 32, [252] [253] [254] . Although computer-assisted screening of TLR regulators is plausible, the rational design of selective TLR modulators still faces enormous challenges and studies are few. Furthermore, there are some new developments in anti-viral targeting of the host factors involved in TLR signaling. BX795, an inhibitor TBK1, potently suppresses multiple strains of HSV-1, including an ACV-resistant HSV-1 strain. BX795 targets Akt and blocks viral protein synthesis by reducing Akt phosphorylation in infected cells, but a more precise antiviral mechanism requires further investigation [255] . Therefore, clarifying the interaction between each TLR and the associated virus is critical for controlling the development of the diseases caused by the herpesviruses. 

Innate sensing of viruses by toll-like receptors

Sweeten PAMPs: role of sugar complexed PAMPs in innate immunity and vaccine biology

Pathogen recognition and innate immunity

TLR7 and TLR9 in SLE: when sensing self goes wrong

Pattern recognition receptors and inflammation

The role of pattern-recognition receptors in innate immunity: update on toll-like receptors

A conserved TLR5 binding and activation hot spot on flagellin

Insights into the dynamic nature of the dsRNA-bound TLR3 complex

Structural basis of TLR5-flagellin recognition and signaling

Crystal structure of the C-terminal domain of mouse TLR9

Structure and function of toll-like receptor 8

Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9

Structural analysis reveals that toll-like receptor 7 is a dual receptor for guanosine and single-stranded RNA

Structural basis of TLR2/TLR1 activation by the synthetic agonist diprovocim

Toll-like receptors as sensors of pathogens

Mycobacterium tuberculosis ESAT6 induces IFN-beta gene expression in Macrophages via TLRs-mediated signaling

Dendritic cells: TLR agonists trigger rapid metabolic changes

TLR stimulation during T-cell activation lowers PD-1 expression on CD8(+) T Cells

TLR function in murine CD4(+) T lymphocytes and their role in inflammation

TLR signaling in B-cell development and activation

Cutting edge: IL-4, IL-21, and IFN-gamma interact To govern T-bet and CD11c expression in TLR-activated B cells

Toll-like receptors: critical proteins linking innate and acquired immunity

Histone deacetylase 6 regulates endothelial MyD88-dependent canonical TLR signaling, lung inflammation, and alveolar remodeling in the developing lung

Evidence of an anti-inflammatory toll-like receptor 9 (TLR 9) pathway in adipocytes

Epithelial cells attenuate toll-like receptor-mediated inflammatory responses in monocytederived macrophage-like cells to mycobacterium tuberculosis by modulating the PI3K/Akt/mTOR signaling pathway

Selenium attenuates high glucose-induced ROS/TLR-4 involved apoptosis of rat cardiomyocyte

Annexin A2 binds to endosomes and negatively regulates TLR4-triggered inflammatory responses via the TRAM-TRIF pathway

The role of acetylation in TLR4-mediated innate immune responses

activation of TLR2 and TLR9 in trigeminal ganglia

Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9

Unmethylated CpG motifs in Toxoplasma gondii DNA induce TLR9-and IFN-beta-dependent expression of alpha-defensin-5 in intestinal epithelial cells

Selectivity of human TLR9 for double cpg motifs and implications for the recognition of genomic DNA

Herpes simplex virus-1 encephalitis in adults: pathophysiology, diagnosis, and management

Calcium spirulan derived from Spirulina platensis inhibits herpes simplex virus 1 attachment to human keratinocytes and protects against herpes labialis

Herpes simplex virus-1 evasion of CD8+ T cell accumulation contributes to viral encephalitis

Induction of multiple miR-200/182 members in the brains of mice are associated with acute herpes simplex virus 1 encephalitis

Herpes simplex virus 2 infection: molecular association with HIV and novel microbicides to prevent disease

Prophylactic herpes simplex virus 2 (HSV-2) vaccines adjuvanted with stable emulsion and toll-like receptor 9 agonist induce a robust HSV-2-specific cell-mediated immune response, protect against symptomatic disease, and reduce the latent viral reservoir

Perspectives on optimal control of varicella and herpes zoster by mass routine varicella vaccination

Varicella zoster virus vasculopathy: the expanding clinical spectrum and pathogenesis

Infectious mononucleosis

Post-transplant lymphoproliferative disorders

EBV infection and glucose metabolism in nasopharyngeal carcinoma

Epstein-Barr virus infection in B-cell Non-Hodgkin's Lymphomas of the oral and maxillofacial region: is there any evidence?

Infectious mononucleosis-like syndrome and gastrointestinal disorders in acute acquired cytomegalovirus infection

Cytomegalovirus-associated infectious mononucleosis-like syndrome accompanied by transient monoclonal expansion of CD8+ T-cells

Human herpesvirus-6 and -7 infections in children: agents of roseola and other syndromes

The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation

Acute hepatitis with periportal confluent necrosis associated with human herpesvirus 6 infection in liver transplant patients

Clinical characteristics and outcome of human herpesvirus-6 encephalitis after allogeneic hematopoietic stem cell transplantation

Kaposi's sarcoma-associated herpesvirus: a lymphotropic human herpesvirus associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease

Kaposi's sarcoma-associated herpesvirus (KSHV): a new viral pathogen associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

Kaposi sarcoma herpesvirus pathogenesis

Herpes simplex virus keratitis. Home Healthc Now

Problematic molecular diagnosis of HSV-1 infection due to a single nucleotide polymorphism in the US7 gene

The miRNAs of herpes simplex virus (HSV)

Herpes simplex virus type 1 Us3 gene deletion influences toll-like receptor responses in cultured monocytic cells

Herpes simplex virus immediateearly ICP0 protein inhibits Toll-like receptor 2-dependent inflammatory responses and NF-kappaB signaling

Herpes simplex virus type 1 dysregulates anti-fungal defenses preventing monocyte activation and downregulating toll-like receptor-2

Role of herpes simplex virus type 1 (HSV-1) glycoprotein K (gK) pathogenic CD8(+) T cells in exacerbation of eye disease

The Us2 gene product of herpes simplex virus 2 modulates NF-kappaB activation by targeting TAK1

Involvement of TLR2 and TLR9 in the anti-inflammatory effects of chlorogenic acid in HSV-1-infected microglia

Direct activation of RIP3/MLKL-dependent necrosis by herpes simplex virus 1 (HSV-1) protein ICP6 triggers host antiviral defense

Role of specific innate immune responses in herpes simplex virus infection of the central nervous system

Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis

TLR2 and TLR9 synergistically control herpes simplex virus infection in the brain

Herpes simplex virus glycoproteins gH/gL and gB bind Toll-like receptor 2, and soluble gH/ gL is sufficient to activate NF-kappaB

Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a triacylated lipopeptide

TLR4-MyD88/Mal-NF-kB axis is involved in infection of HSV-2 in human cervical epithelial cells

Herpes simplex virus type 1 induces simultaneous activation of Toll-like receptors 2 and 4 and expression of the endogenous ligand serum amyloid A in astrocytes

Herpes simplex virus type 1 engages toll like receptor 2 to Recruit macrophages during infection of enteric neurons

Roles of the TRAF6 and Pellino E3 ligases in MyD88 and RANKL signaling

Phosphoinositide-dependent kinase-1 inhibits TRAF6 ubiquitination by interrupting the formation of TAK1-TAB2 complex in TLR4 signaling

The mechanism of activation of IRAK1 and IRAK4 by interleukin-1 and Tolllike receptor agonists

Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling

TAK1-dependent signaling requires functional interaction with TAB2/TAB3

Transforming growth factor beta-activated kinase 1 (TAK1) kinase adaptor, TAK1-binding protein 2, plays dual roles in TAK1 signaling by recruiting both an activator and an inhibitor of TAK1 kinase in tumor necrosis factor signaling pathway

The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes

IKKalpha contributes to canonical NF-kappaB activation downstream of Nod1-mediated peptidoglycan recognition

Lethal encephalitis in myeloid differentiation factor 88-deficient mice infected with herpes simplex virus 1

The herpes simplex virus 1-encoded envelope glycoprotein B activates NF-kappaB through the Toll-like receptor 2 and MyD88/TRAF6-dependent signaling pathway

Type I interferon and NF-kappaB activation elicited by herpes simplex virus gH/gL via alphavbeta3 integrin in epithelial and neuronal cell lines

Lowmolecular weight mannogalactofucans prevent herpes simplex virus type 1 infection via activation of Toll-like receptor 2

Effect of TNF-alpha inhibitors on transcriptional levels of proinflammatory interleukin-33 and Toll-like receptors-2 and -9 in psoriatic plaques

Herpesviral infection and Toll-like receptor 2

Cutting edge: TLR2-mediated proinflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus

Herpes simplex virus type 2 infection triggers AP-1 transcription activity through TLR4 signaling in genital epithelial cells

Requirement of TLR2-mediated signaling for the induction of IL-15 gene expression in human monocytic cells by HSV-1

The role of toll-like receptors in herpes simplex infection in neonates

Herpes simplex virus induces neural oxidative damage via microglial cell Toll-like receptor-2

TLR3 deficiency renders astrocytes permissive to herpes simplex virus infection and facilitates establishment of CNS infection in mice

Tolllike receptor 3 immune deficiency may be causative for HSV-2-associated mollaret meningitis

The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9

The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling

UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes

The chaperone UNC93B1 regulates toll-like receptor stability independently of endosomal TLR transport

Sensing of viral infection and activation of innate immunity by toll-like receptor 3

Toll-like receptors in CNS viral infections

Functional failure of TLR3 and its signaling components contribute to herpes simplex encephalitis

Doublestranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses

Small GTPase Rab8a-recruited Phosphatidylinositol 3-Kinase gamma regulates signaling and cytokine outputs from endosomal tolllike receptors

TIPE2 controls innate immunity to RNA by targeting the phosphatidylinositol 3-kinase-Rac pathway

Epidermal growth factor receptor is essential for Toll-like receptor 3 signaling

c-Src trafficking and co-localization with the EGF receptor promotes EGF ligand-independent EGF receptor activation and signaling

Multiple TLRs activate EGFR via a signaling cascade to produce innate immune responses in airway epithelium

Toll-like receptor 3 associates with c-Src tyrosine kinase on endosomes to initiate antiviral signaling

DNA fingerprinting by means of a nonradioactive probe of sulfonated DNA

TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction

Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway

Akt contributes to activation of the TRIF-dependent signaling pathways of TLRs by interacting with TANK-binding kinase 1

Mechanisms of the TRIF-induced interferon-stimulated response element and NF-kappaB activation and apoptosis pathways

Signaling of apoptosis through TLRs critically involves toll/IL-1 receptor domain-containing adapter inducing IFN-beta, but not MyD88, in bacteria-infected murine macrophages

Induction of the DNA repair gene O6-methylguanine-DNA methyltransferase by dexamethasone in glioblastomas

Cutting edge: NF-kappaB-activating kinase-associated protein 1 participates in TLR3/Toll-IL-1 homology domain-containing adapter molecule-1-mediated IFN regulatory factor 3 activation

Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6

Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response

IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway

IRF3 mediates a TLR3/TLR4-specific antiviral gene program

HSV-1 activates NF-kappaB in mouse astrocytes and increases TNF-alpha and IL-6 expression via Toll-like receptor 3

Poly(I-C)-induced Toll-like receptor 3 (TLR3)-mediated activation of NFkappa B and MAP kinase is through an interleukin-1 receptor-associated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR

TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo

RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation

The IKK complex, a central regulator of NF-kappaB activation

Recognition of herpes simplex viruses: toll-like receptors and beyond

Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling

Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not toll/IL-1 receptor domain-containing adaptor-inducing IFN-beta (TRIF)-dependent pathway in TLR signaling

Herpes simplex virus type-1 induces IFNalpha production via Toll-like receptor 9-dependent and -independent pathways

Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells

Necessity of oligonucleotide aggregation for toll-like receptor 9 activation

TLR9 signals after translocating from the ER to CpG DNA in the lysosome

Rab5 is necessary for the biogenesis of the endolysosomal system in vivo

Rab conversion as a mechanism of progression from early to late endosomes

Molecular dynamics at the endocytic portal and regulations of endocytic and recycling traffics

Endosome maturation

Human VPS34 is required for internal vesicle formation within multivesicular endosomes

Distinct roles of class I and class III phosphatidylinositol 3-kinases in phagosome formation and maturation

Activation of NF-kappa B by nontypeable Hemophilus influenzae is mediated by toll-like receptor 2-TAK1-dependent NIK-IKK alpha /beta-I kappa B alpha and MKK3/6-p38 MAP kinase signaling pathways in epithelial cells

Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells

Interleukin-1 (IL-1) receptor-associated kinase-dependent IL-1-induced signaling complexes phosphorylate TAK1 and TAB2 at the plasma membrane and activate TAK1 in the cytosol

Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9

TLR9 is required for MAPK/NF-kappaB activation but does not cooperate with TLR2 or TLR6 to induce host resistance to Brucella abortus

Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase

Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation

Cell type-specific activation of mitogen-activated protein kinases by CpG-DNA controls interleukin-12 release from antigen-presenting cells

Mechanism and function of a newly identified CpG DNA motif in human primary B cells

The secretion of IL-6 by CpG-ODN-treated cancer cells promotes T-cell immune responses partly through the TLR-9/AP-1 pathway in oral squamous cell carcinoma

Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency

Varicella-zoster virus and herpes simplex virus 1 differentially modulate NKG2D ligand expression during productive infection

Varicella-zoster virus activates inflammatory cytokines in human monocytes and macrophages via Toll-like receptor 2

Immune evasion during varicella zoster virus infection of keratinocytes

IFN-alpha production by human mononuclear cells infected with varicella-zoster virus through TLR9-dependent and -independent pathways

Viral activation of macrophages through TLR-dependent and -independent pathways

TLR3 mutations in adult patients with herpes simplex virus and varicella-zoster virus encephalitis

MicroRNAs of epstein-barr virus control innate and adaptive antiviral immunity

Epstein-barr virus large tegument protein BPLF1 contributes to innate immune evasion through interference with toll-like receptor signaling

Silencing the shutoff protein of Epstein-Barr virus in productively infected B cells points to (innate) targets for immune evasion

EBV lytic-phase protein BGLF5 contributes to TLR9 downregulation during productive infection

Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2

Toll-like receptors signaling: A complex network for NF-kappaB activation in B-cell lymphoid malignancies

EBV-encoded RNA via TLR3 induces inflammation in nasopharyngeal carcinoma

Epstein-barr virus-encoded RNAs: key molecules in viral pathogenesis

Manipulation of the toll-like receptor 7 signaling pathway by epstein-barr virus

The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling

The epstein-barr virus lytic program is controlled by the co-operative functions of two transactivators

Immune activation suppresses initiation of lytic Epstein-Barr virus infection

An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus

TLR9 contributes to the recognition of EBV by primary monocytes and plasmacytoid dendritic cells

Epstein-Barr virus DNA modulates regulatory T-cell programming in addition to enhancing interleukin-17A production via Toll-like receptor 9

Tuning the orchestra: HCMV vs innate immunity

Human cytomegalovirus-encoded US9 targets MAVS and STING signaling to evade type I interferon immune responses

Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease

Human cytomegalovirus tegument protein UL82 Inhibits STING-mediated signaling to evade antiviral immunity

HCMV-encoded US7 and US8 act as antagonists of innate immunity by distinctively targeting TLR-signaling pathways

A specific Toll-like receptor profile on T lymphocytes and values of monocytes correlate with bacterial, fungal, and cytomegalovirus infections in the early period of allogeneic stem cell transplantation

Cytomegalovirus enhances macrophage TLR expression and MyD88-mediated signal transduction to potentiate inducible inflammatory responses

Mast cells as rapid innate sensors of cytomegalovirus by TLR3/TRIF signaling-dependent and -independent mechanisms

Human cytomegalovirus miR-UL112-3p targets TLR2 and modulates the TLR2/IRAK1/NFkappaB signaling pathway

Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2

Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells

The R753Q polymorphism abrogates toll-like receptor 2 signaling in response to human cytomegalovirus

Interferons at age 50: past, current and future impact on biomedicine

MicroRNAs expressed by human cytomegalovirus

Lipopolysaccharide-mediated interferon regulatory factor activation involves TBK1-IKKepsilondependent Lys(63)-linked polyubiquitination and phosphorylation of TANK/I-TRAF

IKAP is a scaffold protein of the Ikap-paB kinase complex

Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins

Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2

Identification of critical residues of the MyD88 death domain involved in the recruitment of downstream kinases

Oncogenically active MYD88 mutations in human lymphoma

A Toll-like receptor recognizes bacterial DNA

CpG motifs in bacterial DNA and their immune effects

Update on human herpesvirus 6 biology, clinical features, and therapy

• fast, convenient online submission • thorough peer review by experienced researchers in your field • rapid publication on acceptance • support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year submit your research ? Choose BMC

Distinct effects of human herpesvirus 6 and human herpesvirus 7 on surface molecule expression and function of CD4+ T cells

Transcriptional down-regulation of CXC chemokine receptor 4 induced by impaired association of transcription regulator YY1 with c-Myc in human herpesvirus 6-infected cells

Human herpesvirus 6 infection impairs Toll-like receptor signaling

The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation

Is there a link between human herpesvirus infection and toll-like receptors in the pathogenesis of pityriasis rosea? A case-control study

Detection of human herpesvirus 8 in the skin of patients with pityriasis rosea

KSHV genome replication and maintenance in latency

The viral interferon regulatory factors of kaposi's sarcoma-associated herpesvirus differ in their inhibition of interferon activation mediated by toll-like receptor 3

TLR-TRIF pathway enhances the expression of KSHV replication and transcription activator

Kaposi's sarcoma-associated herpesvirus reduces cellular myeloid differentiation primary-response gene 88 (MyD88) expression via modulation of Its RNA

Upregulation of the TLR3 pathway by Kaposi's sarcoma-associated herpesvirus during primary infection

Activation of plasmacytoid dendritic cells by Kaposi's sarcoma-associated herpesvirus

TLR4-mediated inflammation promotes KSHVinduced cellular transformation and tumorigenesis by activating the STAT3 pathway

Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirus

Kaposi's sarcoma-associated herpesvirus microRNAs target IRAK1 and MYD88, two components of the toll-like receptor/interleukin-1R signaling cascade, to reduce inflammatory-cytokine expression

The gammaherpesviruses Kaposi's sarcoma-associated herpesvirus and murine gammaherpesvirus 68 modulate the Toll-like receptor-induced proinflammatory cytokine response

Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus-and HIV-1-specific T cell responses

Dendritic cells, macrophages, NK and CD8(+) T lymphocytes play pivotal roles in controlling HSV-1 in the trigeminal ganglia by producing IL1-beta, iNOS and granzyme B

Antiviral signaling through pattern recognition receptors

Topical SMIP-7.7, a toll-like receptor 7 agonist, protects against genital herpes simplex virus type-2 disease in the guinea pig model of genital herpes

Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice

Cloning, expression, and purification of a pathogenesis-related protein from oenanthe javanica and its biological properties

BX-795 inhibits HSV-1 and HSV-2 replication by blocking the JNK/ p38 pathways without interfering with PDK1 activity in host cells

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations